Literature DB >> 9057596

Outcomes after multi-modality treatment of musculoskeletal tumours.

F W Marsden1, C E Swanson.   

Abstract

Outcomes of treatment of musculoskeletal tumours are evaluated for effectiveness of chemotherapy protocols, function obtained after surgery and survival after treatment. Quality of life achieved after multimodality treatment is dependent on a combination of all of these factors. Quality of life varies significantly along the treatment pathway, and continuously through the life of a patient. The patient's perception of outcome is based on the total effect of the disease and its treatment, rather than necessarily focussing on separate items of treatment. We have found that visual analogue scales can be used effectively to gauge the patient's perception of their quality of life. Such a method has shown that, overall, perceptions of quality of life seem to be better for those patients who have undergone successful limb salvage surgery when compared with those who have undergone amputation, but the differences are not as great as might be assumed.

Entities:  

Mesh:

Year:  1997        PMID: 9057596     DOI: 10.1080/17453674.1997.11744711

Source DB:  PubMed          Journal:  Acta Orthop Scand Suppl        ISSN: 0300-8827


  3 in total

1.  Psychosocial and functional outcomes in long-term survivors of osteosarcoma: a comparison of limb-salvage surgery and amputation.

Authors:  Rhonda S Robert; Giulia Ottaviani; Winston W Huh; Shana Palla; Norman Jaffe
Journal:  Pediatr Blood Cancer       Date:  2010-07-01       Impact factor: 3.167

2.  What is the emotional acceptance after limb salvage with an expandable prosthesis?

Authors:  Eric R Henderson; Andrew M Pepper; German A Marulanda; Justin D Millard; G Douglas Letson
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

3.  [Amputation or limb salvage? Assessing quality of life after tumor operations of the lower extremity].

Authors:  A Zahlten-Hinguranage; L Bernd; D Sabo
Journal:  Orthopade       Date:  2003-11       Impact factor: 1.087

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.